Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06807463 · ClinicalTrials.gov registry record · Phase 2

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

A Phase 2 study of Celiac Disease, sponsored by Teva Branded Pharmaceutical Products R&D.

Recruiting
Registry status
Phase 2
Development phase
48
Enrollment target
20
Study locations

NCT06807463 is a Phase 2 study of Celiac Disease that is actively recruiting participants, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 48 participants, below the 1,978-participant average among 24 other Celiac Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06807463, a Phase 2 study of Celiac Disease, is actively recruiting participants, sponsored by Teva Branded Pharmaceutical Products R&D.

RECRUITING
Registry status
Phase 2
Development phase
48 participants
Enrollment target
20
Study locations

Study Summary

The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease. The expected trial duration per participant is approximately 86 weeks.

Conditions Studied

Celiac Disease

Interventions

  • DRUG Placebo
  • DRUG TEV-53408

Study Locations (20)

Other

  • Teva Investigational Site 78139 - Fitzroy
  • Teva Investigational Site 78140 - Maroochydore
  • Teva Investigational Site 78137 - Midland
  • Teva Investigational Site 40063 - Helsinki

Florida

  • Teva Investigational Site 12134 - Inverness
  • Teva Investigational Site 12126 - Miami Lakes
  • Teva Investigational Site 12135 - New Port Richey

Michigan

  • Teva Investigational Site 12132 - Clinton Township
  • Teva Investigational Site 12121 - Wyoming

North Carolina

  • Teva Investigational Site 12125 - Greenville
  • Teva Investigational Site 12127 - Winston-Salem

California

  • Teva Investigational Site 12138 - Murrieta

Colorado

  • Teva Investigational Site 12131 - Colorado Springs

Georgia

  • Teva Investigational Site 12130 - Atlanta

Louisiana

  • Teva Investigational Site 12133 - Marrero

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2025-03-31
Est. Completion 2027-09-14
Phase Phase 2

Sponsor

Teva Branded Pharmaceutical Products R&D

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06807463

The ClinicalTrials.gov registry entry for NCT06807463 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,978-participant average among 24 other Celiac Disease trials with a reported enrollment target (98% lower). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Celiac Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06807463 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Florida, Michigan.

Frequently Asked Questions

What is clinical trial NCT06807463 about?

NCT06807463 is a clinical study titled "A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease". The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. A secondary objective is to further...

What is the current status of trial NCT06807463?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2025-03-31. Estimated completion is 2027-09-14.

What conditions does trial NCT06807463 study?

This clinical trial studies the following conditions: Celiac Disease.

What interventions are being tested in trial NCT06807463?

The interventions under investigation include: Placebo (DRUG), TEV-53408 (DRUG).

Who is sponsoring clinical trial NCT06807463?

This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06807463 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Celiac Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Celiac Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.